Dienogest was synthesized in 1979 in Jena , Germany under the leadership of Kurt Ponsold, was initially referred to as STS-557 .   It was found that its potency was 10 times that of levonorgestrel .  The first product on the market to contain dienogest was a combined oral contraceptive pill (with ethinylestradiol), Valette, introduced in 1995 and made by Jenapharm .  In 2007, dienogest was introduced as Dinagest in Japan for the treatment of endometriosis, and it was subsequently marketed for this indication as Visanne in Europe and Australia in December 2009 and April 2010, respectively.  Qlaira was introduced in Europe in 2009 and Natazia was introduced in the United States in 2010. 
After oral administration, sumatriptan is rapidly absorbed, 70% of the maximum plasma concentration is reached after 45 minutes. After receiving 100 mg of the maximum concentration in plasma is on average 54 ng / ml. Bioavailability is 14% as a result of the intensive first-pass metabolism and incomplete to plasma proteins is low trenbolone enanthate 200. Sumatriptan is metabolized by the action of monoamine oxidase A main metabolite – indoleacetic analog output of sumatriptan, preferably in the urine in the form of free acid and glucuronide conjugate. This metabolite has no activity against serotonin receptors. Migraine attacks, apparently no significant effect on the pharmacokinetics of sumatriptan ingestable.